Shanghai Henlius Biotech has formed a strategic collaboration with Sandoz to develop and commercialize up to 10 monoclonal antibody and antibody-drug conjugate biosimilars globally, excluding China. The partnership builds on their 2025 oncology biosimilars deal and includes upfront and milestone payments totaling up to $322 million, with Henlius expecting invoiced revenue of $100.5 million in 2026. This collaboration leverages Henlius' biologics development and manufacturing capabilities and Sandoz's global commercialization network, aiming to accelerate global market access for these biosimilars. Key products include biosimilars for cetuximab, evolocumab, and belimumab, with most still in early development stages.
VICI Properties is rated a Buy with a $30 price target, offering a potential 26% price increase plus an 8% dividend yield. The company maintains strong fundamentals including full occupancy, triple-net leases, and a long average lease term of nearly ...
QXO, Inc. is currently trading below its book value and at a market capitalization less than its recent acquisition of TopBuild, despite building a leading platform in building products distribution. The company reported a 70% year-over-year revenue ...
eBay CEO Jamie Iannone has sold company shares worth $2.3 million. This sale comes as eBay's stock has delivered a 12% return over the past year. The move may reflect personal financial planning or confidence in the company's current valuation. Inves...
PEPE, a meme coin, gained 15.4% over the past week, reaching $0.00000393 as of September 20, 2026. Despite rumors of whale buying, a fund launch, and a token buyback, no solid evidence supports these claims, which mostly appear as promotional content...
Bitcoin's 50-day moving average recently crossed above its 200-day average, a pattern known as a golden cross often seen as a buy signal. Historical data since 2014 shows that Bitcoin's price rose 90 days after eight out of eleven golden crosses, ave...
